On the basis of previous cell line studies and clinical trials showing efficacy of the combination of BRAF inhibitors with MEK inhibitors in BRAFV600E-mutant human cancers, we examined the sensitivity of BRAFV600E-mutated PTC organoids with both single and double agent treatment of vemurafenib and trametinib. This evidence concerns the gene BRAF and cancer.